¹û¶³´«Ã½

Independent non-executive director Jörn Rausing seems to be bullish on the long-term outlook for the company

As a growth stock with defensive potential, the pharma giant increasingly stands out among the FTSE’s top brass

The insolvency practice is gearing up for growth as the economic outlook darkens

Plus a table of this week's major director transactions

Amid efforts to boost recurring revenues, helped by a big recent acquisition, the Aim-traded firm’s bright prospects could attract a suitor of its own

As government stimulus promises to further light up the US solar industry, this fund’s growth looks underwritten

Amid mounting pressure on margins and sales, Fever-Tree's shares no longer justify their premium price

Profitable, plugged into growth trends and trading below book value, Costain's shares look to have bottomed

Non executive shows commitment to the cause

Founder bullish On The Beach